TrialBritish journal of clinical pharmacology2026

Safety, tolerability and pharmacokinetics of DNDI-6148, a novel agent for leishmaniasis: A randomized, controlled, single ascending dose study in healthy participants.

Jean-Yves Gillon et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.